The US Food and Drug Administration has scheduled a two-day workshop starting 5 April to discuss how transbronchoscopic thermal ablation (TTA) devices may be used to treat oligometastases of the lung (OML). If successful, ablation therapy may be less invasive and more effective than other current cancer therapies.
The FDA said that earlier diagnosis and improved treatment of primary tumors has led to the need for better treatments of OML tumors, which develop when cancer cells from an...